Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR

Lantern Pharma Inc.

2024-Q2 EPS reported -$0.97

Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.
LP-300 Harmonic Phase 2 lead-in (7 pts): 86% clinical benefit rate, 43% objective response rate, no dose-limiting toxicities.
LP-184 Phase 1A: 7 cohorts dosed, no DLTs; LP-284 third cohort dosing, no DLTs; both on track.
RADR platform collaboration with Oregon Therapeutics for XCE853; Starlight Therapeutics advancing STAR-001 for recurrent GBM.
Japanese patent issued for LP-284; Webinar Wednesdays launched for AI and oncology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.